Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

Abstract Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventua...

Full description

Bibliographic Details
Published in:	Journal of Experimental & Clinical Cancer Research
Main Authors:	Lina Merkens, Verena Sailer, Davor Lessel, Ella Janzen, Sarah Greimeier, Jutta Kirfel, Sven Perner, Klaus Pantel, Stefan Werner, Gunhild von Amsberg
Format:	Article
Language:	English
Published:	BMC 2022-02-01
Subjects:	Aggressive variant prostate cancer Small cell prostate cancer Neuroendocrine prostate cancer Neuroendocrine transdifferentiation
Online Access:	https://doi.org/10.1186/s13046-022-02255-y

Similar Items

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
by: Zoe R. Maylin, et al.
Published: (2024-12-01)

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets
by: Jun Jiang, et al.
Published: (2024-10-01)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
by: Rodolfo Montironi, et al.
Published: (2020-04-01)

Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review
by: Maolin Xiao, et al.
Published: (2024-05-01)

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation
by: Yu Wang, et al.
Published: (2025-05-01)

Neuroendocrine differentiation in prostate cancer – a review
by: R. Popescu, et al.
Published: (2015-12-01)

Mixed adenocarcinoma and neuroendocrine prostate cancer: a case report
by: Rittu Hingorani, et al.
Published: (2014-11-01)

Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation
by: Xueping Ma, et al.
Published: (2021-09-01)

Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression
by: Monica Fedele, et al.
Published: (2024-02-01)

Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study
by: YouZhi Wang, et al.
Published: (2022-09-01)

Local Therapy Can Enhance the Prognosis of Certain Patients with Pathologically Diagnosed Neuroendocrine Prostate Carcinoma
by: Shoichi Kimura, et al.
Published: (2025-05-01)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
by: Julia Lipianskaya, et al.
Published: (2014-08-01)

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review
by: Mohammad Abufaraj, et al.
Published: (2024-03-01)

Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation
by: Andrew Michael Asberry, et al.
Published: (2022-01-01)

A systematic review of primary large cell neuroendocrine carcinoma of the prostate
by: Ngan Nguyen, et al.
Published: (2024-03-01)

Primary mosaic neuroendocrine/adenocarcinoma of the prostate
by: Kálmán Almási, et al.
Published: (2024-07-01)

Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer
by: Bo Shao, et al.
Published: (2025-12-01)

Endocrine and paracrine characteristics of neuroendocrine prostate cancer
by: Tarana Arman, et al.
Published: (2022-11-01)

Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs
by: Eva Slabáková, et al.
Published: (2021-12-01)

MicroRNA-1205 Regulation of FRYL in Prostate Cancer
by: Michelle Naidoo, et al.
Published: (2021-07-01)

A Complete Response to Combined Immunotherapy in a Patient with an ATM plus SF3B1 Mutation and a Moderate Tumor Mutational Burden with a High-Grade Treatment-Emergent Neuroendocrine Prostate Cancer: Case Report and Review of the Literature
by: Helena Ferreira Bruzzi Porto, et al.
Published: (2024-08-01)

177LU-PSMA AND 177LU-DOTATATE AS THERAPY ALTERNATIVES FOR METACHRONOUS TRANSDIFFERENTIATED PROSTATE AND NEUROENDOCRINE TUMORS - CASE REPORT
by: Beatriz Birelli do Nascimento, et al.
Published: (2024-04-01)

Neuroendocrine cancer of the prostate. Two case reports
by: Tamás Kullmann, et al.
Published: (2022-03-01)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
by: Marco Bergamini, et al.
Published: (2022-07-01)

Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 –2018)
by: Shihua Wang, et al.
Published: (2023-06-01)

A case of mixed neuroendocrine carcinoma–acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer
by: Junichi Ikeda, et al.
Published: (2024-11-01)

Epigenetic abnormalities and neuroendocrine differentiation in prostate cancer
by: G. A. Kovchenko, et al.
Published: (2025-03-01)

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
by: Zheng Wang, et al.
Published: (2020-01-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC)
by: Huan Xu, et al.
Published: (2022-05-01)

The Current Therapeutic Landscape for Metastatic Prostate Cancer
by: Anastasia Bernal, et al.
Published: (2024-03-01)

Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
by: Giovanni Farinea, et al.
Published: (2024-08-01)

Role of MicroRNAs in Neuroendocrine Prostate Cancer
by: Amritha Sreekumar, et al.
Published: (2022-03-01)

Primary neuroendocrine prostate cancer with adrenal gland metastasis
by: Antonio Yaromin Muñoz López, et al.
Published: (2022-01-01)

Androgen-targeted therapy induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention
by: Mannan eNouri, et al.
Published: (2014-12-01)

Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival
by: Giordano F, et al.
Published: (2019-12-01)

Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer
by: Tatyana Gavrikova, et al.
Published: (2023-03-01)

Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer
by: Yini Zhu, et al.
Published: (2023-01-01)

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer
by: Giovanni Pecoraro, et al.
Published: (2025-02-01)

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation
by: Joel Vargas Ahumada, et al.
Published: (2022-06-01)